Literature DB >> 11176490

Erbium: YAG versus holmium:YAG lithotripsy.

J M Teichman1, K F Chan, P P Cecconi, N S Corbin, A D Kamerer, R D Glickman, A J Welch.   

Abstract

PURPOSE: We test the hypothesis that erbium:YAG (Er:YAG) lithotripsy is more efficient than holmium:YAG (Ho:YAG) lithotripsy.
MATERIALS AND METHODS: Human calculi composed of greater than 97% calcium oxalate monohydrate and cystine were studied. Calculi were irradiated in water using Er:YAG or Ho:YAG lasers. Er:YAG lithotripsy was done with a 425 microm sapphire optical fiber at a pulse energy of 50 mJ at 10 Hz. Ho:YAG lithotripsy was performed with a 365 microm low hydroxy optical fiber at a pulse energy of 500 mJ at 10 Hz or a 425 microm sapphire optical fiber at a pulse energy of 50 mJ at 10 Hz. Fragmentation was defined as the initial stone mass minus the final dominant fragment mass and normalized for incident laser fluence (energy per unit area of fiber tip).
RESULTS: Mean fragmentation plus or minus standard deviation for calcium oxalate monohydrate was 38 +/- 27 mg for Er:YAG and 22 +/- 6 for Ho:YAG (low hydroxy silica fiber) versus 5 +/- 1 for Ho:YAG (sapphire fiber, p = 0.001). When fragmentation was normalized for incident laser fluence given different optical fiber sizes, mean fragmentation efficiency was 53.6 +/- 38.7 g-microm2/J for Er:YAG lithotripsy compared with 22.6 +/- 6.4 for Ho:YAG (low hydroxy silica fiber) lithotripsy (p = 0.04). Mean cystine fragmentation was 15 +/- 3 mg for Er:YAG versus 9 +/- 1 for Ho:YAG (sapphire fiber, p = 0.0005).
CONCLUSIONS: Er:YAG lithotripsy is more efficient than Ho:YAG lithotripsy.

Entities:  

Mesh:

Year:  2001        PMID: 11176490

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  2 in total

Review 1.  Intracorporeal lithotripsy.

Authors:  Peter Alken
Journal:  Urolithiasis       Date:  2017-12-04       Impact factor: 3.436

Review 2.  Lasers in clinical urology: state of the art and new horizons.

Authors:  Andrew J Marks; Joel M H Teichman
Journal:  World J Urol       Date:  2007-03-28       Impact factor: 3.661

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.